Skip to main content
Acute radiation syndrome treatment gains Orphan Drug designation
8/23/2019

The FDA granted Chrysalis BioTherapeutics' investigational candidate TP508, or rusalatide acetate, Orphan Drug status, indicated for acute radiation syndrome, or radiation sickness. A regenerative peptide drug, TP508 instigates revascularization and the repair of multiple tissues.

Full Story: